National
9 U.S. senators to Harkin: Time to move on ENDA
Bipartisan group calls for vote on non-discrimination bill
A bipartisan group of nine senators is backing the idea of having the Senate panel with jurisdiction over the Employment Non-Discrimination Act advance the legislation to the floor by a committee vote.
The group is asking for Sen. Tom Harkin (D-Iowa), chair of the Senate Health, Education, Labor & Pensions Committee, to hold a markup on ENDA in the wake of the panel’s hearing on the legislation last week and the senator’s remarks to the Washington Blade immediately afterward that he wanted “to poll the committee” about moving the bill forward.
Sen. Mark Kirk is among those calling for an ENDA markup (Washington Blade file photo by Michael Key)
In the week after the hearing, the Blade solicited statements from the offices of all 22 members of the Senate panel on whether they want to see the committee move the legislation to the Senate floor. Those who responded affirmatively were spokespersons for Sens. Jeff Merkley (D-Ore.), ENDA’s lead sponsor, as well as Sens. Barbara Mikulski (D-Md.), Patty Murray (D-Wash.), Bernard Sanders (I-Vt.), Bob Casey (D-Pa.), Al Franken (D-Minn.), Michael Bennet (D-Colo.), Richard Blumenthal (D-Conn.) and Mark Kirk (R-Ill.), the only Republican on the panel who responded to the Blade’s inquiry.
All 12 Democrats on the panel — as well as Kirk, an original co-sponsor of the bill — are among the 41 total co-sponsors of ENDA, so the bill should have no trouble moving out of committee. The legislation would bar employers in most situations in the public and private workforce from discriminating against workers because of their sexual orientation or gender identity.
Sanders’ office accompanied his call for a committee vote on ENDA with a statement saying the time is now to pass ENDA to end workforce discrimination against LGBT people.
“As I’ve said many times before, discrimination of any kind is not what America is supposed to be about,” Sanders said. “Yet only 16 states, including my own state of Vermont, and D.C. currently prohibit discrimination based on sexual orientation and gender identity. I will fully support Sen. Merkley and Chairman Harkin in their efforts to move the Employment Non-Discrimination Act out of committee, because no Americans should have to live with the fear of losing their jobs simply because of who they are.”
The support that Murray’s office conveyed to the Blade echoes the sentiment she expressed about moving the legislation forward during the committee hearing last week. Murray was explicit in calling for a markup, saying she wants to see ENDA pass out of committee “expeditiously.” In response, Harkin said, “I hope so.”
But speaking to the Washington Blade after the hearing, Harkin was non-committal about holding a markup, saying he wants to speak with panel members before moving forward.
Senate HELP Committee Chair Tom Harkin (Blade file photo by Michael Key)
“I’m going to poll my committee and see,” Harkin said. “Right now, I’m kind of up to here in getting [Food & Drug Administration] bill through, as you know. We got it through the Senate; we’ve got to work with the House on that trying to get that put to bed, and then I’m going to poll the committee and see what we want to do.”
The Senate HELP Committee didn’t respond to a request for comment on the possibility of holding a markup on ENDA. It’s unclear whether the seven senators who expressed support for a markup to the Blade’s solicitation is enough support for Harkin to schedule a markup.
Tico Almeida, president of Freedom to Work, said a markup would enable the committee to make technical changes to the bill before taking it to the Senate floor for final passage.
“Senate rules allow leader Reid to bring ENDA to the floor of the Senate without a committee vote, but a committee mark-up would present a good opportunity for Chairman Harkin to make technical improvements to ENDA, for example, by fixing the legal loophole created by a bad Supreme Court decision called Gross vs. FBL Financial,” Almeida said. “Mr. Harkin recently introduced legislation to fix the same loophole in the age discrimination statute, and ENDA needs the same fix to be incorporated into the bill.”
Ian Thompson, legislative representative for the American Civil Liberties Union, also backed the idea of a committee markup as a way to advance ENDA.
“The Senate HELP Committee should move forward with a markup of this critical and long overdue legislation that will allow American workers who stand side-by-side at the workplace and contribute with equal measure in their jobs to also stand on the same equal footing under the law,” Thompson said.
Thompson added the committee should make modifications to the bill when it comes up for consideration: (a) narrowing the legislation’s exemption so that it doesn’t provide religious organizations “with a blank check” to discriminate against LGBT people for any reason and not just religious teachings, and (b) removing a provision that expands the Defense of Marriage Act and allows employers in states where same-sex couples can legally marry to treat married gay employees as unmarried for the purposes of employee benefits.
Reporting the legislation to the floor would be similar to what Sen. Patrick Leahy (D-Vt.) did for the Respect for Marriage Act, legislation that would repeal the Defense of Marriage Act. In November, Leahy held a markup on the bill in the Senate Judiciary Committee, passing the bill via a party-line vote.
A committee markup may be the furthest extent to which ENDA can advance during the 112th Congress. The 41 co-sponsors of the legislation fall significantly short of the 60 votes needed to overcome a Senate filibuster. Additionally, it’s highly unlikely that the Republican-controlled House would consider ENDA as long as House Speaker John Boehner (R-Ohio) is the presiding officer of that chamber.
The office of Sen. Jeff Bingaman (D-N.M.) reiterated the senator’s support for ENDA in response to the Blade inquiry without explicitly calling for a markup. Jude McCartin, a Bingaman spokesperson said, “Sen. Bingaman is a cosponsor of the bill and as such intends to vote for it.” McCartin didn’t respond to follow up inquiries to clarify whether this means Bingaman wants to see a markup.
But some of the committee members who responded affirmatively to the idea of a markup — Merkley, Murray, Casey and Kirk — went further and volunteered they also want to see a floor vote on the legislation despite the lack of assured passage of the legislation. Even a vote that failed would demonstrate where senators stand on the bill — and which lawmakers ENDA supporters should work to expel on Election Day.
Merkley expressed support for the idea of a markup and floor vote in response to a question from the Washington Blade during a conference call with reporters following the ENDA hearing last week.
“I support any effort that takes this issue forward whether it’s a markup in committee or it going straight to the floor,” Merkley said. “I’ll defer to the leadership of the committee on the most effective legislative strategy, but I think it is long past time for the Senate as a whole to debate and vote on this bill.”
In a statement to the Blade, Casey expressed support for a Senate vote on ENDA in a statement accompanying his backing a markup of the bill.
“I hope that the Senate moves quickly toward bipartisan passage of the Employment Non-Discrimination Act,” Casey said. “This common-sense legislation ensures that employees are judged on their skills and abilities in the workplace and not on their sexual orientation or gender identity and I am hopeful that it will see swift passage.”
Kirk’s support for both a markup and floor vote on ENDA puts him ahead of many Democrats on where he wants to take the legislation. Kate Dickens, a Kirk spokesperson, said, “Sen. Kirk is supportive of committee passage and floor consideration of ENDA.”
Christian Berle, deputy executive director of the Log Cabin Republicans, said his organization supports Kirk’s call to advance the legislation as far as possible in the Senate.
“Jobs and the economy must be the first priority for Congress, and the freedom to work is fundamental to getting all Americans back to work,” Berle said. “Log Cabin Republicans support Sen. Mark Kirk’s effort to secure a markup both in committee and on the floor. Sen. Harry Reid remains the majority leader and could easily schedule a vote to maintain his commitment to equality and should not delay in doing so.”
Support for a floor vote on ENDA echoes a letter that Freedom to Work sent to Senate Majority Leader Harry Reid (D-Nev.) calling for a floor vote this summer on the legislation. The letter notes that Reid said during a 2009 Human Rights Campaign dinner in Utah a floor vote on ENDA would take place “soon” — but has yet to happen — as well as the Blade’s questioning of then-White House Press Secretary Robert Gibbs at the start of this Congress.
In response to a question on whether the administration sees values in passing ENDA in one chamber of Congress, Gibbs acknowledged, “there’s no doubt that whenever you get something done in one [chamber], you’re closer to certainly seeing it come to fruition.”
A number of LGBT groups — including the Human Rights Campaign and the National Gay & Lesbian Task Force — had previously called for a markup of ENDA as they sought a Senate hearing on the legislation. But the call for a full Senate vote on ENDA wasn’t as unified.
Fred Sainz, HRC’s vice president of communications, wasn’t explicit in calling for a floor vote when asked by the Blade if his organization wants to see the Senate take the legislation that far during this Congress.
“HRC supports advancing the bill in the smartest, most strategic fashion and at the most opportune time,” Sainz said. “We will continue to work with our ally organizations as well as fair-minded members of both houses of Congress to find that time.”
Stacey Long, the Task Force’s director of public policy and government affairs at the National Gay and Lesbian Task Force, said her organization wants to see a Senate vote, but only after the committee has first marked up the bill.
“We want it to follow the procedure — first voted out of committee, then sent to the Senate floor, followed by a full Senate vote,” Long said.
But Almeida insisted that a Senate floor vote on ENDA is the best possible route for the bill in the immediate future regardless of what action the committee takes.
“The most opportune time for a Senate vote on ENDA is right away,” Almeida said. “We should not accept excuses for further delay on a Senate vote for legislation supported by super-majorities of the American people. … ENDA now has Republicans calling for a full Senate vote, and that is consistent with the White House’s position that right now the administration prefers a congressional vote on ENDA rather than an executive order that is waiting for the president’s signature.”
Almeida was referring to the proposed executive order barring federal contractors from discriminating against workers based on sexual orientation and gender identity. In April, the White House announced it wouldn’t issue such a directive at this time.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
Advocates say MTG bill threatens trans youth, families, and doctors
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Far-right José Antonio Kast elected Chile’s next president
Lighting candles in a time of exhaustion
In real estate, trust the process
-
Politics2 days agoLGBTQ Democrats say they’re ready to fight to win in 2026
-
District of Columbia2 days ago
Brian Footer suspends campaign for Ward 1 D.C. Council seat
-
Chile5 days ago
Far-right José Antonio Kast elected Chile’s next president
-
Opinions3 days ago
Lighting candles in a time of exhaustion
